Kaposi Sarcoma malady

Genetic diseases, Cancer diseases, Infectious diseases, Rare diseases categories

Aliases & Classifications for Kaposi Sarcoma

About this section
46OMIM, 8Disease Ontology, 9diseasecard, 44Novoseek, 48Orphanet, 32MedlinePlus, 61UMLS, 56SNOMED-CT, 27ICD9CM, 33MeSH, 39NCIt, 26ICD10 via Orphanet, 62UMLS via Orphanet, 34MESH via Orphanet, 25ICD10
See all sources

Aliases & Descriptions for Kaposi Sarcoma:

Name: Kaposi Sarcoma 46 8 44 61
Kaposi's Sarcoma 8 48 32
Kaposi's Sarcoma of Gastrointestinal Sites 8 61
Kaposi's Sarcoma of Lymph Nodes 8 61
Kaposi's Sarcoma of Soft Tissue 8 61
Kaposi's Sarcoma of Conjunctiva 8 61
Gallbladder Kaposi's Sarcoma 8 61
Kaposi's Sarcoma of Palate 8 61
Kaposi's Sarcoma of Cornea 8 61
Kaposi's Sarcoma of Lung 8 61
Kaposi's Sarcoma of Skin 8 61
Cardiac Kaposi's Sarcoma 8 61
Gastric Kaposi's Sarcoma 8 61
Kaposi's Sarcoma of Central Nervous System 8
Central Nervous System Kaposi's Sarcoma 8
Kaposi's Sarcoma of the Gallbladder 8
Kaposi Sarcoma, Susceptibility to 9
Lymphadenopathic Kaposi's Sarcoma 8
Kaposi's Sarcoma of the Prostate 8
Kaposi's Sarcoma of Soft Tissues 8
Kaposi's Sarcoma of Esophagus 8
Conjunctival Kaposi's Sarcoma 8
Soft Tissue Kaposi's Sarcoma 8
Esophageal Kaposi's Sarcoma 8
Kaposi's Sarcoma of the Cns 8
Intestinal Kaposi's Sarcoma 8
Lymph Node Kaposi's Sarcoma 8
Cutaneous Kaposi's Sarcoma 8
Pulmonary Kaposi's Sarcoma 8
Kaposi's Sarcoma of Heart 8
Prostate Kaposi's Sarcoma 8
Kaposi's Sarcoma of Penis 8
Esophageal Kaposi Sarcoma 61
Corneal Kaposi's Sarcoma 8
Kaposi's Sarcoma of Anus 8
Prostate Kaposi Sarcoma 61
Palate Kaposi's Sarcoma 8
Kaposi's Sarcoma, Skin 8
Kaposi's Sarcoma, Lung 8
Penis Kaposi's Sarcoma 8
Penile Kaposi Sarcoma 61
Anal Kaposi's Sarcoma 8
Anal Kaposi Sarcoma 61


Characteristics (Orphanet epidemiological data):

kaposi's sarcoma:
Inheritance: Not applicable; Prevalence: 1-9/1000000 (Europe),1-9/100000 (Europe); Age of onset: Adult; Age of death: adult

Summaries for Kaposi Sarcoma

About this section
OMIM:46 Kaposi sarcoma (KS) is an invasive angioproliferative inflammatory condition that occurs commonly in men infected with... (148000) more...

MalaCards based summary: Kaposi Sarcoma, also known as kaposi's sarcoma, is related to sarcoma and classic kaposi sarcoma, and has symptoms including autosomal dominant inheritance, edema and hypermelanotic macule. An important gene associated with Kaposi Sarcoma is IL6 (interleukin 6 (interferon, beta 2)), and among its related pathways are Malaria and HIF-1 signaling pathway. The drugs etoposide and interferon alfa-2a and the compounds tocilizumab and pegasys have been mentioned in the context of this disorder. Affiliated tissues include lung, skin and prostate, and related mouse phenotypes are liver/biliary system and respiratory system.

Disease Ontology:8 A connective tissue cancer that derives from lymphatic endothelium, and derives from spindle cells, results in formation of vascular channels that fill with blood cells, has material basis in human herpesvirus 8 (hhv8).

MedlinePlus:32 Kaposi's sarcoma is a cancer that causes patches of abnormal tissue to grow under the skin, in the lining of the mouth, nose, and throat or in other organs. the patches are usually red or purple and are made of cancer cells and blood cells. the red and purple patches often cause no symptoms, though they may be painful. if the cancer spreads to the digestive tract or lungs, bleeding can result. lung tumors can make breathing hard. before the hiv/aids epidemic, ks usually developed slowly. in hiv/aids patients, though, the disease moves quickly. treatment depends on where the lesions are and how bad they are. treatment for hiv itself can shrink the lesions. however, treating ks does not improve survival from hiv/aids itself. nih: national cancer institute

Related Diseases for Kaposi Sarcoma

About this section

Diseases related to Kaposi Sarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 145)
idRelated DiseaseScoreTop Affiliating Genes
1sarcoma31.9TAT, OSM, CD34, PECAM1
2classic kaposi sarcoma31.9IFNA1, CD34, IL6, TAT
3acquired immunodeficiency syndrome31.4IFNA1, IL6, TAT
4pyogenic granuloma30.8CD34, PECAM1
5arthritis30.7IL6, OSM
6leukopenia30.6IL6, IFNA2, IFNA1
7lymphangioma30.6CD34, PECAM1
8angiosarcoma30.5CD34, PECAM1
9hepatitis30.5IFNA2, TAT, IFNA1, HGF
10malaria30.4TAT, PECAM1
11hepatitis c30.4IL6R, IFNA2, IFNA1
12hemangioma30.2VEGFA, PECAM1, IFNA2, CD34, FGF4
13rheumatoid arthritis29.5VEGFA, OSM, IL6, IL6R, PECAM1, IL6ST
14leukemia29.1IFNA1, OSM, IL6, IFNA2, CD34, FGF4
15endemic kaposi sarcoma10.7
16primary effusion lymphoma10.7
17polyarteritis nodosa10.6IFNA2
18lymphomatoid granulomatosis10.6IFNA2
20inflammatory bowel disease 110.5IL6
21capillary hemangioma10.5CD34
23fibrous histiocytoma10.5CD34
24meningioma, familial10.5CD34
25central retinal vein occlusion10.5VEGFA
26hemangioendothelioma10.5CD34, IFNA2
27diabetic macular edema10.5VEGFA
28epithelioid hemangioendothelioma10.4CD34, IFNA2
29castleman's disease10.4
30vascular cancer10.4CD34, IFNA2
31cryoglobulinemia, familial mixed10.4IFNA1, IFNA2
32cryoglobulinemia10.4IFNA1, IFNA2
33hepatitis d10.4IFNA1, IFNA2
34colon kaposi sarcoma10.4
35poems syndrome10.4IL6, VEGFA
36hypothyroidism10.3IFNA2, IFNA1
37sezary's disease10.3IFNA2, IFNA1
38hodgkin lymphoma10.3
39secondary syphilis10.3
41essential thrombocythemia10.3IFNA2, IFNA1
42splenomegaly10.3IFNA1, IFNA2
43thrombocytosis10.3IFNA2, IL6, IFNA1
44factor vii deficiency10.3VEGFA, IFNA2, IFNA1
45neutropenia10.3IFNA2, IFNA1, CD34
46renal cell carcinoma10.3IFNA2, IFNA1, VEGFA
47adrenal hyperplasia, congenital, due to 11-beta-hydroxylase deficiency10.3IFNA2, IFNA1
48multicentric castleman’s disease10.3IL6R, IL6
49acute erythroid leukemia10.3TAT, OSM, IL6ST

Graphical network of the top 20 diseases related to Kaposi Sarcoma:

Diseases related to kaposi sarcoma

Symptoms for Kaposi Sarcoma

About this section

Symptoms by clinical synopsis from OMIM:


Clinical features from OMIM:


HPO human phenotypes related to Kaposi Sarcoma:

id Description Frequency HPO Source Accession
1 autosomal dominant inheritance HP:0000006
2 edema HP:0000969
3 hypermelanotic macule HP:0001034
4 neoplasm HP:0002664

Drugs & Therapeutics for Kaposi Sarcoma

About this section

FDA approved drugs:

id Drug Name Active Ingredient(s)13 Pharmaceutical Company Approval Date
Doxil13 38 DOXORUBICIN HYDROCHLORIDE Alza Approved June 1999
FDA Label: Doxil
Malady that Drug Treats: ovarian cancer that is refractory to other first-line therapies
Indications and Usage:13 DOXIL is an anthracycline topoisomerase II inhibitor indicated for:; Ovarian cancer (1.1); After failure of platinum-based chemotherapy.; AIDS-related Kaposi s Sarcoma (1.2); After failure of prior systemic chemotherapy or intolerance to such therapy.; Multiple Myeloma (1.3); In combination with bortezomib in patients who have not previously; received bortezomib and have received at least one prior therapy.
DrugBank Targets:11 1. DNA; 2. DNA topoisomerase 2-alpha
Mechanism of Action:13 
Target: nucleic acid; synthesis
Action: inhibitor
FDA: The active ingredient of DOXIL is doxorubicin HCl. The mechanism of action of; doxorubicin HCl is thought to be related to its ability to bind DNA and inhibit nucleic acid; synthesis. Cell structure studies have demonstrated rapid cell penetration and perinuclear; Reference ID: 3733596; 17 ; ; ; ; ; chromatin binding, rapid inhibition of mitotic activity and nucleic acid synthesis, and; induction of mutagenesis and chromosomal aberrations.
Intron A13 38 INTERFERON ALFA-2B Schering-Plough Approved December 1997/ Approved December 1995/ Approved March 1997
FDA Label: Intron A
Malady that Drug Treats: non-Hodgkin's lymphoma/ malignant melanoma / Hepatitis C
Indications and Usage:13 Hairy Cell Leukemia INTRON® A is indicated for the treatment of patients 18 years of; age or older with hairy cell leukemia.; Malignant Melanoma INTRON A is indicated as adjuvant to surgical treatment in; patients 18 years of age or older with malignant melanoma who are free of disease but; at high risk for systemic recurrence, within 56 days of surgery.; Follicular Lymphoma INTRON A is indicated for the initial treatment of clinically; aggressive (see Clinical Pharmacology) follicular Non-Hodgkin s Lymphoma in; conjunction with anthracycline-containing combination chemotherapy in patients 18; years of age or older. Efficacy of INTRON A therapy in patients with low-grade, lowtumor; burden follicular Non-Hodgkin s Lymphoma has not been demonstrated.; Condylomata Acuminata INTRON A is indicated for intralesional treatment of selected; patients 18 years of age or older with condylomata acuminata involving external; surfaces of the genital and perianal areas (see DOSAGE AND ADMINISTRATION).; The use of this product in adolescents has not been studied.; AIDS-Related Kaposi's Sarcoma INTRON A is indicated for the treatment of selected; patients 18 years of age or older with AIDS-Related Kaposi's Sarcoma. The likelihood; of response to INTRON A therapy is greater in patients who are without systemic symptoms, who have limited lymphadenopathy and who have a relatively intact immune; system as indicated by total CD4 count.; Chronic Hepatitis C INTRON A is indicated for the treatment of chronic hepatitis C in; patients 18 years of age or older with compensated liver disease who have a history of; blood or blood-product exposure and/or are HCV antibody positive. Studies in these; patients demonstrated that INTRON A therapy can produce clinically meaningful effects; on this disease, manifested by normalization of serum alanine aminotransferase (ALT); and reduction in liver necrosis and degeneration.; A liver biopsy should be performed to establish the diagnosis of chronic hepatitis.; Patients should be tested for the presence of antibody to HCV. Patients with other; causes of chronic hepatitis, including autoimmune hepatitis, should be excluded. Prior; to initiation of INTRON A therapy, the physician should establish that the patient has; compensated liver disease. The following patient entrance criteria for compensated liver; disease were used in the clinical studies and should be considered before INTRON A; treatment of patients with chronic hepatitis C:; No history of hepatic encephalopathy, variceal bleeding, ascites, or other; clinical signs of decompensation; Bilirubin Less than or equal to 2 mg/dL; Albumin Stable and within normal limits; Prothrombin Time Less than 3 seconds prolonged; WBC Greater than or equal to 3000/mm3; Platelets Greater than or equal to 70,000/mm3; Serum creatinine should be normal or near normal.; Prior to initiation of INTRON A therapy, CBC and platelet counts should be; evaluated in order to establish baselines for monitoring potential toxicity. These tests; should be repeated at Weeks 1 and 2 following initiation of INTRON A therapy, and; monthly thereafter. Serum ALT should be evaluated at approximately 3-month intervals; to assess response to treatment (see DOSAGE AND ADMINISTRATION).; Patients with preexisting thyroid abnormalities may be treated if thyroidstimulating; hormone (TSH) levels can be maintained in the normal range by medication.; TSH levels must be within normal limits upon initiation of INTRON A treatment and TSH; testing should be repeated at 3 and 6 months (see PRECAUTIONS, Laboratory; Tests).; INTRON A in combination with REBETOL® is indicated for the treatment of; chronic hepatitis C in patients 3 years of age and older with compensated liver disease; previously untreated with alpha interferon therapy and in patients 18 years of age and; older who have relapsed following alpha interferon therapy. See REBETOL prescribing; information for additional information. Chronic Hepatitis B INTRON A is indicated for the treatment of chronic hepatitis B in; patients 1 year of age or older with compensated liver disease. Patients who have been; serum HBsAg positive for at least 6 months and have evidence of HBV replication; (serum HBeAg positive) with elevated serum ALT are candidates for treatment. Studies; in these patients demonstrated that INTRON A therapy can produce virologic remission; of this disease (loss of serum HBeAg) and normalization of serum aminotransferases.; INTRON A therapy resulted in the loss of serum HBsAg in some responding patients.; Prior to initiation of INTRON A therapy, it is recommended that a liver biopsy be; performed to establish the presence of chronic hepatitis and the extent of liver damage.; The physician should establish that the patient has compensated liver disease. The; following patient entrance criteria for compensated liver disease were used in the; clinical studies and should be considered before INTRON A treatment of patients with; chronic hepatitis B:; No history of hepatic encephalopathy, variceal bleeding, ascites, or other; signs of clinical decompensation; Bilirubin Normal; Albumin Stable and within normal limits; Prothrombin Time Adults less than 3 seconds prolonged; Pediatrics less than or equal to 2 seconds prolonged; WBC Greater than or equal to 4000/mm3; Platelets Adults greater than or equal to 100,000/mm3; Pediatrics greater than or equal to 150,000/mm3; Patients with causes of chronic hepatitis other than chronic hepatitis B or chronic; hepatitis C should not be treated with INTRON A. CBC and platelet counts should be; evaluated prior to initiation of INTRON A therapy in order to establish baselines for; monitoring potential toxicity. These tests should be repeated at treatment Weeks 1, 2,; 4, 8, 12, and 16. Liver function tests, including serum ALT, albumin, and bilirubin,; should be evaluated at treatment Weeks 1, 2, 4, 8, 12, and 16. HBeAg, HBsAg, and; ALT should be evaluated at the end of therapy, as well as 3- and 6-months posttherapy,; since patients may become virologic responders during the 6-month period; following the end of treatment. In clinical studies in adults, 39% (15/38) of responding; patients lost HBeAg 1 to 6 months following the end of INTRON A therapy. Of; responding patients who lost HBsAg, 58% (7/12) did so 1 to 6 months post-treatment.; A transient increase in ALT greater than or equal to 2 times baseline value (flare); can occur during INTRON A therapy for chronic hepatitis B. In clinical trials in adults; and pediatrics, this flare generally occurred 8 to 12 weeks after initiation of therapy and; was more frequent in responders (adults 63%, 24/38; pediatrics 59%, 10/17) than in; nonresponders (adults 27%, 13/48; pediatrics 35%, 19/55). However, in adults and; pediatrics, elevations in bilirubin greater than or equal to 3 mg/dL (greater than or equal; to 2 times ULN) occurred infrequently (adults 2%, 2/86; pediatrics 3%, 2/72) during; therapy. When ALT flare occurs, in general, INTRON A therapy should be continued unless signs and symptoms of liver failure are observed. During ALT flare, clinical; symptomatology and liver function tests including ALT, prothrombin time, alkaline; phosphatase, albumin, and bilirubin, should be monitored at approximately 2-week; intervals (see WARNINGS).
DrugBank Targets:11 1. Interferon alpha/beta receptor 2; 2. Interferon alpha/beta receptor 1
Mechanism of Action:13 
Target: intracellular oncogene expression, natural killer and cytotoxic T-cells, microphage, cytokine production
Action: stimulation, induction (unspecified effects on oncogene expression)
FDA: -
Taxol13 38 PACLITAXEL Bristol-Myers Squibb Approved August 1997
FDA Label: Taxol
Malady that Drug Treats: Kaposi's Sarcoma
Indications and Usage:13 Paclitaxel Injection, USP is indicated as subsequent therapy for the treatment of advanced carcinoma of; the ovary. As first-line therapy, Paclitaxel Injection, USP is indicated in combination with cisplatin.; Paclitaxel Injection, USP is indicated for the adjuvant treatment of node-positive breast cancer; administered sequentially to standard doxorubicin-containing combination chemotherapy.. In the clinical; trial, there was an overall favorable effect on disease-free and overall survival in the total population of; patients with receptor-positive and receptor-negative tumors, but the benefit has been specifically demonstrated by available data (median follow-up 30 months) only in the patients with estrogen and; progesterone receptor-negative tumors (see CLINICAL STUDIES, Breast Carcinoma).; Paclitaxel Injection, USP is indicated for the treatment of breast cancer after failure of combination; chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Prior therapy; should have included an anthracycline unless clinically contraindicated.; Paclitaxel Injection, USP, in combination with cisplatin, is indicated for the first-line treatment of nonsmall; cell lung cancer in patients who are not candidates for potentially curative surgery and/or radiation; therapy.; Paclitaxel Injection, USP is indicated for the second-line treatment of AIDS-related Kaposi s sarcoma.
DrugBank Targets:11 1. Apoptosis regulator Bcl-2; 2. Tubulin beta-1 chain; 3. Nuclear receptor subfamily 1 group I member 2; 4. Microtubule-associated protein 4; 5. Microtubule-associated protein 2; 6. Microtubule-associated protein tau
Mechanism of Action:13 
Target: microtubules
Action: promoter of assembly & preventor of depolymerization
FDA: Paclitaxel is a novel antimicrotubule agent that promotes the assembly of microtubules from tubulin; dimers and stabilizes microtubules by preventing depolymerization. This stability results in the inhibition; of the normal dynamic reorganization of the microtubule network that is essential for vital interphase and; mitotic cellular functions. In addition, paclitaxel induces abnormal arrays or  bundles of microtubules; throughout the cell cycle and multiple asters of microtubules during mitosis.; Following intravenous administration of paclitaxel, paclitaxel plasma concentrations declined in a; biphasic manner. The initial rapid decline represents distribution to the peripheral compartment and; elimination of the drug. The later phase is due, in part, to a relatively slow efflux of paclitaxel from the; peripheral compartment.; Pharmacokinetic parameters of paclitaxel following 3- and 24-hour infusions of paclitaxel at dose levels; of 135 and 175 mg/m2; were determined in a Phase 3 randomized study in ovarian cancer patients and are; summarized in the following table:

Drug clinical trials:

Search ClinicalTrials for Kaposi Sarcoma

Search NIH Clinical Center for Kaposi Sarcoma

Inferred drug relations via UMLS61/NDF-RT40:

Genetic Tests for Kaposi Sarcoma

About this section

Anatomical Context for Kaposi Sarcoma

About this section

MalaCards organs/tissues related to Kaposi Sarcoma:

Lung, Skin, Prostate, Lymph node, Heart, Endothelial, T cells, B cells, Bone marrow, Bone, Liver, Adrenal gland, Monocytes

Animal Models for Kaposi Sarcoma or affiliated genes

About this section

Publications for Kaposi Sarcoma

About this section

Articles related to Kaposi Sarcoma:

(show top 50)    (show all 244)
Concomitant Kaposi sarcoma and multicentric Castleman's disease in a heart transplant recipient. (25169666)
Role of IRF4 in IFN-stimulated gene induction and maintenance of Kaposi sarcoma-associated herpesvirus latency in primary effusion lymphoma cells. (23804715)
Angiomatous Kaposi Sarcoma: A Variant That Mimics Hemangiomas. (24067801)
Isolated oral Kaposi sarcoma in an HIV-negative patient: a case report. (24341128)
Iatrogenic colorectal Kaposi sarcoma complicating a refractory ulcerative colitis in a human immunodeficiency negative-virus patient. (24396560)
(18)F-FDG PET/CT findings in a case with HIV (-) Kaposi Sarcoma. (24119549)
Kaposi sarcoma in an patient with atopic dermatitis treated with ciclosporin. (24265347)
Bone marrow findings in HIV-positive patients with Kaposi sarcoma herpesvirus-associated multicentric Castleman disease. (23596117)
Tocilizumab Monotherapy in a Patient with Rheumatoid Arthritis and Iatrogenic Kaposi Sarcoma. (24307431)
Treatments for classic Kaposi sarcoma: a systematic review of the literature. (22695100)
Oral medicine case book 50: HIV associated Kaposi sarcoma. (23971290)
Efficacy of 5% imiquimod cream in a patient with classic Kaposi sarcoma. (22826720)
Sequence analysis of Kaposi sarcoma-associated herpesvirus (KSHV) microRNAs in patients with multicentric Castleman disease and KSHV-associated inflammatory cytokine syndrome. (22448005)
Recent advances in Kaposi sarcoma herpesvirus-associated multicentric Castleman disease. (22729151)
Kaposi sarcoma in association with molluscum contagiosum: an uncommon diagnosis in a single biopsy and potential diagnostic pitfall. (22262366)
Hsp90 inhibitors are efficacious against Kaposi Sarcoma by enhancing the degradation of the essential viral gene LANA, of the viral co-receptor EphA2 as well as other client proteins. (23209418)
High-dose zidovudine plus valganciclovir for Kaposi sarcoma herpesvirus-associated multicentric Castleman disease: a pilot study of virus-activated cytotoxic therapy. (21487108)
Delayed-type hypersensitivity in classic Kaposi sarcoma patients and controls. (21245864)
Classic Kaposi sarcoma. (21788419)
Immune reconstitution and risk of Kaposi sarcoma and non-Hodgkin lymphoma in HIV-infected adults. (21572307)
I^-Synuclein is a promising new marker for staining reactive follicular dendritic cells, follicular dendritic cell sarcoma, Kaposi sarcoma, and benign and malignant vascular tumors. (21959308)
Pilot study of oral valganciclovir therapy in patients with classic Kaposi sarcoma. (21450998)
Paediatric intussusception caused by acquired immunodeficiency syndrome-associated Kaposi sarcoma. (20535484)
A case of Kaposi sarcoma-associated herpesvirus/human herpesvirus 8-unrelated but Epstein-Barr virus-positive primary effusion lymphoma-like lymphoma in the setting of human immunodeficiency virus and hepatitis C virus infection. (20929325)
Common vascular endothelial growth factor variants and risk for posttransplant Kaposi sarcoma. (20683431)
Complex N-linked glycans on Asn-89 of Kaposi sarcoma herpes virus-encoded interleukin-6 mediate optimal function by affecting cytokine protein conformation. (19690161)
The role of Ephs, Ephrins, and growth factors in Kaposi sarcoma and implications of EphrinB2 blockade. (18836096)
Results of radiation therapy for treatment of classic Kaposi sarcoma. (19298767)
Cutaneous tumors, massive lymphadenopathy, and secondary lymphedema in a 16-year-old boy--quiz case. African/endemic Kaposi sarcoma (KS): lymphadenopathic form. (18794470)
Pegylated liposomal doxorubicin as second-line therapy in the treatment of patients with advanced classic Kaposi sarcoma: a retrospective study. (18098221)
Treatment of classic Kaposi sarcoma with a nicotine dermal patch: a phase II clinical trial. (18384551)
Stimulation of c-Myc transcriptional activity by vIRF-3 of Kaposi sarcoma-associated herpesvirus. (17728244)
Relationship between human herpesvirus 8 loads and disease stage in classic Kaposi sarcoma patients. (17403447)
Conservation of virally encoded microRNAs in Kaposi sarcoma--associated herpesvirus in primary effusion lymphoma cell lines and in patients with Kaposi sarcoma or multicentric Castleman disease. (17262705)
Influence of HLA alleles on shedding of Kaposi sarcoma-associated herpesvirus in saliva in an African population. (17299710)
Rapidly progressive classic Kaposi sarcoma in an adolescent: response to interferon alfa therapy and biological correlates. (16445793)
Activation of Src kinase Lyn by the Kaposi sarcoma-associated herpesvirus K1 protein: implications for lymphomagenesis. (15665117)
Regulation of microfilament organization by Kaposi sarcoma-associated herpes virus-cyclin.CDK6 phosphorylation of caldesmon. (16115893)
Ephrin B2 expression in Kaposi sarcoma is induced by human herpesvirus type 8: phenotype switch from venous to arterial endothelium. (15471957)
Mono/oligoclonal pattern of Kaposi Sarcoma-associated herpesvirus (KSHV/HHV-8) episomes in primary effusion lymphoma cells. (15700304)
Kaposi sarcoma-associated herpesvirus (KSHV) induces heme oxygenase-1 expression and activity in KSHV-infected endothelial cells. (14726403)
Selective expression of stromal-derived factor-1 in the capillary vascular endothelium plays a role in Kaposi sarcoma pathogenesis. (12907452)
The Kaposi sarcoma-associated herpesvirus (KSHV) induces cellular interleukin 6 expression: role of the KSHV latency-associated nuclear antigen and the AP1 response element. (11781250)
Lytic replication-associated protein (RAP) encoded by Kaposi sarcoma-associated herpesvirus causes p21CIP-1-mediated G1 cell cycle arrest through CCAAT/enhancer-binding protein-alpha. (12145325)
Receptor engagement by viral interleukin-6 encoded by Kaposi sarcoma-associated herpesvirus. (11698289)
Long-term remission of Kaposi sarcoma-associated herpesvirus-related multicentric Castleman disease with anti-CD20 monoclonal antibody therapy. (11719390)
A single 13-kilobase divergent locus in the Kaposi sarcoma-associated herpesvirus (human herpesvirus 8) genome contains nine open reading frames that are homologous to or related to cellular proteins. (9032328)
Human herpesvirus 8 in classic Kaposi sarcoma. (9147730)
The detection of acquired immunodeficiency syndrome-associated Kaposi sarcoma cells in pleural effusion by CD34 immunostain. (7690682)
Intralesional treatment of classical Kaposi sarcoma with interferon-alpha]. (1361927)

Variations for Kaposi Sarcoma

About this section

Expression for genes affiliated with Kaposi Sarcoma

About this section
Search GEO for disease gene expression data for Kaposi Sarcoma.

Pathways for genes affiliated with Kaposi Sarcoma

About this section

Pathways related to Kaposi Sarcoma according to GeneCards Suite gene sharing:

(show all 48)
idSuper pathways (with members indented)ScoreTop Affiliating Genes
19.8IL6, HGF, PECAM1
29.8IL6R, IL6, VEGFA
39.8IL6R, VEGFA, IL6
Show member pathways
Show member pathways
9.6FGF5, FGF4
Show member pathways
9.6IL6, IL6ST, IL6R
79.6IL6ST, IL6, IL6R
89.6IL6, IL6R, IL6ST
99.6IL6, IL6R, IL6ST
109.6IL6, IL6R, IL6ST
Show member pathways
Translation Non genomic rapid action of Androgen Receptor59
9.6IL6R, IL6, IL6ST
Show member pathways
9.6IL6ST, IL6R, IL6
Show member pathways
9.6IL6ST, IL6R, IL6
149.5IL6, CD34, IL6R
159.5IFNA1, IFNA2, IL6
169.5IFNA2, IL6, IFNA1
179.5IL6, IFNA2, IFNA1
Show member pathways
9.5IFNA2, IL6, IFNA1
199.5OSM, IL6, IL6ST
Show member pathways
9.4IL6ST, IL6, IL6R, HGF
Show member pathways
9.4FGF3, FGF5, FGF4
Show member pathways
9.4FGF3, FGF4, FGF5
Show member pathways
9.4FGF3, FGF5, FGF4
Show member pathways
9.4FGF4, FGF3, FGF5
Show member pathways
9.2IL6, FGF5, FGF4, HGF
Show member pathways
9.2FGF5, FGF4, HGF, IL6
Show member pathways
9.2HGF, IL6, FGF5, FGF4
Show member pathways
9.2HGF, IL6, FGF5, FGF4
Show member pathways
9.2FGF5, IL6, HGF, FGF4
Show member pathways
9.2STIM1, FGF4, FGF3, FGF5
Show member pathways
Show member pathways
9.0IL6, FGF5, FGF4, HGF, FGF3
Show member pathways
Signaling Pathways in Glioblastoma36
Show member pathways
Show member pathways
8.9FGF5, FGF4, HGF, IL6, IL6ST
388.7HGF, FGF3, FGF5, VEGFA, FGF4, IL6
Show member pathways
8.7FGF5, FGF3, CD34, FGF4, STIM1
Show member pathways
Show member pathways
Type III interferon signaling36
Show member pathways
Show member pathways
7.9FGF4, FGF3, IFNA1, FGF5, IFNA2, IL6
Show member pathways
7.7OSM, CCR8, IL6, IL6R, HGF, FGF4
Show member pathways
7.7CCR8, IL6, IL6R, HGF, FGF4, FGF5
Show member pathways
7.7HGF, FGF4, IL6, FGF5, CCR8, IL6R
Show member pathways

Compounds for genes affiliated with Kaposi Sarcoma

About this section

Compounds related to Kaposi Sarcoma according to GeneCards Suite gene sharing:

(show top 50)    (show all 103)
idCompoundScoreTop Affiliating Genes
1tocilizumab44 1111.2IL6R, IL6
2pegasys4410.0IFNA2, IFNA1
3entecavir449.9IFNA1, IFNA2
4filgrastim44 1110.9HGF, OSM, IL6, IFNA2
5imiquimod44 60 28 1112.9IL6, IFNA1, IFNA2
6temozolomide44 1110.8IFNA1, VEGFA, IFNA2
7isotretinoin44 1110.8IFNA2, IFNA1, HGF
8suramin44 28 1111.8VEGFA, HGF, IL6R, FGF4
9ursodeoxycholic acid44 24 1111.7HGF, IFNA2, IFNA1
10infliximab44 50 1111.7VEGFA, IFNA2, IL6
11prostacyclin449.7CYSLTR2, HGF, VEGFA, PECAM1
122,5-oligoadenylate449.7TAT, IL6, IFNA2, IFNA1
13hyaluronic acid44 2410.7VEGFA, HGF, IL6, OSM
14neopterin449.6IFNA1, IFNA2, IL6, IL6R
15rituximab44 50 1111.6IL6, IL6R, IFNA1, IFNA2
16methotrexate50 44 1111.6TAT, IL6, HGF, IL6R
17tgf beta1449.6OSM, IL6, HGF, FGF4
18leucovorin44 50 1111.6IFNA2, IFNA1, VEGFA
19indomethacin44 28 60 1112.6TAT, HGF, IFNA2, OSM, IL6
20gp 130449.6IL6ST, IL6R, IL6, OSM
21cyclophosphamide44 50 1111.5IFNA2, VEGFA, HGF, IFNA1
22acth449.4IL6, IL6ST, IFNA2, OSM, CYSLTR2
23fibrinogen449.4PECAM1, OSM, IL6, IL6R, TAT
24matrigel449.4FGF4, PECAM1, VEGFA, OSM, HGF
255fluorouracil449.3IFNA2, VEGFA, HGF, IFNA1
26thalidomide44 50 60 1112.3IFNA1, VEGFA, IL6R, IFNA2, IL6, HGF
27genistein44 28 60 1 24 1114.2VEGFA, IL6, OSM, IL6ST, HGF, TAT
28actinomycin d449.2IFNA1, IL6, TAT, PECAM1, HGF, VEGFA
29cyclosporin a44 28 6011.1TAT, HGF, IL6R, IL6, IFNA1, PECAM1
30ccl344 2810.1IFNA1, TAT, IL6, CCR8
31oxygen44 249.9TAT, HGF, IFNA2, CYSLTR2, PECAM1, SLC7A11
32pge2448.9HGF, IL6R, CYSLTR2, OSM, VEGFA, IL6
33glucose448.9IL6R, TAT, FGF4, IFNA2, PECAM1, IL6
34retinoid448.9IFNA1, IFNA2, HGF, FGF4
35ifn-alpha448.9IL6, IL6ST, IFNA2, IFNA1, IL6R, OSM
36cholesterol44 28 24 1111.9IL6ST, IL6, IL6R, PECAM1, OSM, FGF4
37prednisolone44 28 1110.9IL6, IFNA2, IL6ST, IFNA1, IL6R, TAT
38histamine44 28 2410.8OSM, TAT, IL6, HGF, IL6R, PECAM1
39alanine448.7OSM, IFNA1, IFNA2, IL6ST, IL6, HGF
40heparin44 28 24 1111.6FGF5, FGF4, FGF3, PECAM1, CYSLTR2, VEGFA
41dexamethasone44 50 28 1111.4VEGFA, TAT, HGF, IL6R, IL6, IL6ST
42lipid448.4PECAM1, CYSLTR2, OSM, TAT, IFNA2, IL6ST
43cycloheximide448.2PECAM1, VEGFA, IL6ST, IFNA1, HGF, IL6
44agar448.1TAT, CD34, FGF4, FGF3, PECAM1, HGF
45rantes448.1IL6, IFNA1, PECAM1, OSM, CCR8, TAT
46estrogen448.0IFNA2, VEGFA, PECAM1, OSM, FGF4, IL6ST
47thymidine44 248.8FGF5, IL6, PECAM1, HGF, IL6R, CD34
48retinoic acid44 248.4IL6R, HGF, TAT, CD34, IL6, IL6ST
49tyrosine446.4IL6, IFNA2, IFNA1, OSM, VEGFA, CYSLTR2
50vegf446.1IFNA1, TAT, IL6R, FGF4, FGF3, FGF5

GO Terms for genes affiliated with Kaposi Sarcoma

About this section

Cellular components related to Kaposi Sarcoma according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1oncostatin-M receptor complexGO:00059009.7IL6ST, OSM
2interleukin-6 receptor complexGO:00058969.5IL6ST, IL6, IL6R
3extracellular spaceGO:00056157.7FGF5, PECAM1, VEGFA, OSM, IFNA2, IL6ST
4extracellular regionGO:00055767.6VEGFA, IFNA2, IL6ST, IL6, IL6R, HGF

Biological processes related to Kaposi Sarcoma according to GeneCards Suite gene sharing:

(show all 36)
idNameGO IDScoreTop Affiliating Genes
1hepatic immune responseGO:000238410.4IL6R, IL6
2negative regulation of collagen biosynthetic processGO:003296610.4IL6R, IL6
3neutrophil mediated immunityGO:000244610.3IL6, IL6R
4positive regulation of leukocyte chemotaxisGO:000269010.3IL6R, IL6
5negative regulation of cysteine-type endopeptidase activity involved in apoptotic processGO:004315410.2VEGFA, IL6, HGF
6ciliary neurotrophic factor-mediated signaling pathwayGO:007012010.2IL6R, IL6ST
7positive regulation of chemokine productionGO:003272210.1IL6R, IL6
8negative regulation of hormone secretionGO:004688810.1IL6, OSM
9negative regulation of neuron deathGO:0190121510.1CD34, IL6
10monocyte chemotaxisGO:000254810.1IL6, IL6R
11glomerular endothelium developmentGO:007201110.1CD34, PECAM1
12platelet degranulationGO:000257610.0HGF, VEGFA, PECAM1
13positive chemotaxisGO:005091810.0HGF, VEGFA
14interleukin-6-mediated signaling pathwayGO:007010210.0IL6ST, IL6, IL6R
15positive regulation of peptidyl-serine phosphorylationGO:003313810.0IL6, OSM, VEGFA
16glutamate metabolic processGO:000653610.0TAT, CD34
17positive regulation of ERK1 and ERK2 cascadeGO:00703749.9CYSLTR2, IL6, FGF4
18positive regulation of MAPK cascadeGO:00434109.9OSM, IL6, IL6R
19platelet activationGO:00301689.9PECAM1, VEGFA, IL6, HGF
20positive regulation of acute inflammatory responseGO:00026759.9IL6, IL6ST, OSM
21positive regulation of angiogenesisGO:00457669.8CYSLTR2, VEGFA, CD34
22positive regulation of osteoblast differentiationGO:00456699.8IL6ST, IL6, IL6R, HGF
23positive regulation of tyrosine phosphorylation of Stat3 proteinGO:00425179.8IL6R, IL6, IL6ST, IFNA2
24cytokine-mediated signaling pathwayGO:00192219.7IFNA2, IL6ST, IL6, IL6R
25defense response to Gram-negative bacteriumGO:00508299.7IL6R, IL6
26positive regulation of peptidyl-tyrosine phosphorylationGO:00507319.6VEGFA, OSM, IL6, IL6R, HGF
27leukocyte migrationGO:00509009.6SLC7A11, CD34, PECAM1
28negative regulation of apoptotic processGO:00430669.5VEGFA, IL6ST, IL6, HGF, FGF4
29cell-cell signalingGO:00072679.5FGF5, FGF3, FGF4, IFNA2
30phosphatidylinositol-mediated signalingGO:00480159.4FGF5, FGF3, FGF4
31insulin receptor signaling pathwayGO:00082869.4FGF5, FGF3, FGF4
32blood coagulationGO:00075969.4PECAM1, VEGFA, STIM1, IFNA2, HGF, SLC7A11
33positive regulation of transcription from RNA polymerase II promoterGO:00459449.3FGF4, HGF, IL6, OSM, VEGFA
34fibroblast growth factor receptor signaling pathwayGO:00085439.3FGF4, FGF3, FGF5
35positive regulation of cell divisionGO:00517819.1VEGFA, OSM, FGF4, FGF3, FGF5
36positive regulation of cell proliferationGO:00082848.3FGF5, VEGFA, OSM, IL6ST, IL6, IL6R

Molecular functions related to Kaposi Sarcoma according to GeneCards Suite gene sharing:

(show all 9)
idNameGO IDScoreTop Affiliating Genes
1chemoattractant activityGO:004205610.0HGF, VEGFA
2interleukin-6 bindingGO:00199819.9IL6ST, IL6R
3interleukin-6 receptor activityGO:00049159.9IL6ST, IL6R
4interleukin-6 receptor bindingGO:00051389.8IL6ST, IL6, IL6R
5ciliary neurotrophic factor receptor activityGO:00048979.7IL6R, IL6ST
6fibroblast growth factor receptor bindingGO:00051049.5FGF5, FGF3, FGF4
7cytokine activityGO:00051259.4VEGFA, OSM, IFNA2, IL6
8growth factor activityGO:00080838.5FGF5, FGF3, FGF4, HGF, IL6, OSM
9protein bindingGO:00055156.9PECAM1, VEGFA, STIM1, CCNK, IFNA2, IL6ST

Sources for Kaposi Sarcoma

About this section
26ICD10 via Orphanet
34MESH via Orphanet
47OMIM via Orphanet
57SNOMED-CT via Orphanet
62UMLS via Orphanet